PriceTargets.com logo

Prime Medicine - PRME Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.13
  • Forecasted Upside: 650.00%
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 9 Buy Ratings
  • 1 Strong Buy Ratings
$1.75 As of 03/17/2025 05:00 PM ET
▼ -0.04 (-2.23%)

This chart shows the closing price for PRME by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$1.75Closing price on 03/17/25:
Get New Prime Medicine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRME and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRME

Analyst Price Target is $13.13
▲ +650.00% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Prime Medicine in the last 3 months. The average price target is $13.13, with a high forecast of $18.00 and a low forecast of $10.00. The average price target represents a 650.00% upside from the last price of $1.75.

This chart shows the closing price for PRME for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/254/26$1.20$5.40$9.60$14$18Closing price on 03/17/25: $1.75High$18.00Average$13.13Low$10.00




Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in Prime Medicine. This rating has held steady since November 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/15/2025
  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/17/2025

Latest Recommendations

  • 1 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/3/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/3/2025Chardan CapitalReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
2/28/2025WedbushReiterated RatingOutperform$12.00
12/10/2024Citizens JmpUpgradeStrong-Buy
12/10/2024JMP SecuritiesInitiated CoverageOutperform$10.00
12/3/2024GuggenheimReiterated RatingBuy ➝ Buy$18.00 ➝ $18.00
11/13/2024Chardan CapitalLower TargetBuy ➝ Buy$17.00 ➝ $15.00
11/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
10/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
10/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
8/9/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
8/8/2024WedbushReiterated RatingOutperform$12.00
5/20/2024HC WainwrightInitiated CoverageBuy$10.00
5/16/2024CitigroupUpgradeNeutral ➝ Buy$10.00
5/13/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$16.00 ➝ $15.00
5/7/2024Jefferies Financial GroupReiterated RatingBuy ➝ Buy$23.00 ➝ $15.00
4/23/2024WedbushReiterated RatingOutperform ➝ Outperform$12.00
4/22/2024Chardan CapitalInitiated CoverageBuy$17.00
4/8/2024TD CowenInitiated CoverageBuy
4/2/2024WedbushInitiated CoverageOutperform$12.00
3/5/2024GuggenheimLower TargetBuy ➝ Buy$24.00 ➝ $20.00
1/16/2024Stifel NicolausDowngradeBuy ➝ Hold$18.00 ➝ $9.00
12/8/2023CitigroupInitiated CoverageNeutral$10.00
11/7/2023JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$27.00 ➝ $26.00
10/9/2023BMO Capital MarketsInitiated CoverageOutperform$19.00
9/6/2023JonestradingInitiated CoverageBuy$20.00
8/14/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$21.00 ➝ $19.00
7/31/2023GuggenheimInitiated CoverageBuy$24.00
(Data available from 3/18/2020 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/19/2024
  • 5 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 6 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2025
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2025
  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2025

Current Sentiment

  • 5 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Prime Medicine logo
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.
Read More

Today's Range

Now: $1.75
Low: $1.73
High: $1.85

50 Day Range

MA: $2.65
Low: $1.72
High: $3.29

52 Week Range

Now: $1.75
Low: $1.71
High: $8.27

Volume

1,005,170 shs

Average Volume

1,084,821 shs

Market Capitalization

$229.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.85

Frequently Asked Questions

What sell-side analysts currently cover shares of Prime Medicine?

The following sell-side analysts have issued research reports on Prime Medicine in the last twelve months: Chardan Capital, Citigroup Inc., Citizens Jmp, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., JMP Securities, JPMorgan Chase & Co., StockNews.com, TD Cowen, and Wedbush.
View the latest analyst ratings for PRME.

What is the current price target for Prime Medicine?

0 Wall Street analysts have set twelve-month price targets for Prime Medicine in the last year. Their average twelve-month price target is $13.13, suggesting a possible upside of 650.0%. Guggenheim has the highest price target set, predicting PRME will reach $18.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $10.00 for Prime Medicine in the next year.
View the latest price targets for PRME.

What is the current consensus analyst rating for Prime Medicine?

Prime Medicine currently has 9 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRME will outperform the market and that investors should add to their positions of Prime Medicine.
View the latest ratings for PRME.

What other companies compete with Prime Medicine?

Other companies that are similar to Prime Medicine include Xencor, Replimune Group, Phibro Animal Health, Day One Biopharmaceuticals and Zymeworks. Learn More about companies similar to Prime Medicine.

How do I contact Prime Medicine's investor relations team?

Prime Medicine's physical mailing address is 21 Erie Street, Cambridge MA, 02139. The company's listed phone number is 617-564-0013 and its investor relations email address is hannah.deresiewicz@sternir.com. The official website for Prime Medicine is primemedicine.com. Learn More about contacing Prime Medicine investor relations.